Clinical Observation Of Intravitreal Injection Of Ranibizumab For Treatment Of Choroidal Neovascularization

ObjectiveChoroid neovascularization (choroidal neovascular, CNV) is one of the main form of intraocular angiogenesis,is important causes of blindness in ocular fundus diseases, such as age-related macular degeneration(AMD),idiopathic choroidal neovascular (ICNV), pathologic myopia(PM),polypoidal choroidal vasculopathy (PCV). This study by comparing the observation of ranibizumab for CNV aims to evaluate the effective and to investigate therapeutic strategies for patients.MethodsThe patients were in Tianjin Eye Hospital from2012-8to2013-1, confirmed by clinical examination of CNV with ranibizumab.31cases accept the therapy of ranibizumab, reference to the treatment guide line of AMD,then according to the illness to choose repeated injections(3+PRN group).49cases accept the therapy of1+PRN.A11patients were followed-up12months. The changes of best corrected visual acuity (BCVA), the thickness of CNV and the leakage of CNV lesions were compared before with after the treatment between two treatment groups. To observation all of the changes in BCVA and CRT before and after12months of treatment. The treatment times in12months were analyzed at the12-month visit in two different treatment groups. To observe the changes of BCVA,CRT, the leakage of CNV during two different treatment groups between different CNV diseases. Closely observed the incidence of complications during follow-up, such as changes in intraocular pressure, retinal pigment epithelium tear, endophthalmitis and other injection or drug related adverse reaction or systemic adverse reactions.Results1. Comparison between the3+PRN group and the1+PRN groupAMD group:Between the two groups, there are not statistical differences before and after treatment during follow-up(P>0.05). The mean treatment times are3.35and2.93in two groups. By calculating, there is no statistical difference(P>0.05).PCV group:Between two groups, there are not statistical differences before and after treatment during follow-up (P>0.05). The mean treatment times are3.29and 2.89in two groups. By calculating, there is no statistical difference (P>0.05).ICNV group:Between two groups, there are not statistical differences before and after treatment during follow-up (P>0.05). The mean treatment times are3.00and1.62in two groups. By calculating, there is statistical difference (P=0.00.)PM group:Between two groups, there are not statistical differences before and after treatment during follow-up (P>0.05). The mean treatment times are3.00and2.08in two groups. By calculating, there is statistical difference (P=0.00.)2. Observation differ CNV disease groups before and after IVRFollow-up12months, there are all statistical differences in BCVA and CRT of four groups (P<0.05). There are statistical differences in BCVA and CRT between AMD group and ICNV group during follow-up12months (P<0.05).3. Follow-up duration varied from12to16months(mean:13.60months). There were no ocular or systemic adverse events during follow-up.1AMD patient experienced transient elevated intraocular pressure,24mmHg. After1week follow-up, found intraocular pressure returned to normal without dealing.1case happened subconjunctival hemorrhage in ICNV group, without dealing, back to normal after2weeks.Conclusion1. IVR was effective and safe for treatment of CNV. It could improve visual acuity,reduce retinal edema and the leakage of CNV lesions.2. During the12months follow-up period,.the most obvious effective occurs1month after IVR. The effective of IVR is better than other diseases in ICNV.3. Reducing retinal edema and normalizing the retinal thickness is the key to improve visual.4. The treatment time is less in1+PRN treatment method.1+PRN treatment method can reduce the risk of injections, and at the same time reduce the economic burden of patients.